Anzeige
Mehr »
Donnerstag, 05.06.2025 - Börsentäglich über 12.000 News
Kupfer wird knapp! Jetzt mischen sich Medien ein - und ein Explorer liefert die Story zur Fantasie
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3CWUQ | ISIN: US28658R1068 | Ticker-Symbol:
NASDAQ
04.06.25 | 21:56
1,300 US-Dollar
0,00 % 0,000
1-Jahres-Chart
CLIMB BIO INC Chart 1 Jahr
5-Tage-Chart
CLIMB BIO INC 5-Tage-Chart

Aktuelle News zur CLIMB BIO Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiClym: ARD Money Maker portraitiert Solarpunk-Macher Clym1
22.05.BTIG sets Climb Bio stock Buy rating, $7 target2
19.05.Climb Bio, Inc.: Climb Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)88WELLESLEY HILLS, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases,...
► Artikel lesen
14.05.Climb Bio GAAP EPS of -$0.311
14.05.Climb Bio, Inc. - 10-Q, Quarterly Report-
CLIMB BIO Aktie jetzt für 0€ handeln
14.05.Climb Bio, Inc. - 8-K, Current Report1
01.04.Climb Bio, Inc. - S-8, Securities to be offered to employees in employee benefit plans2
25.03.Climb Bio, Inc. - 8-K, Current Report1
25.03.Climb Bio, Inc.: Climb Bio Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Updates552Received Clearance from the U.S. Food and Drug Administration (FDA) for Clinical Trials of Budoprutug in Primary Membranous Nephropathy (pMN), Immune Thrombocytopenia (ITP), and Systemic Lupus Erythematosus...
► Artikel lesen
25.03.Climb Bio, Inc. - 10-K, Annual Report2
24.02.Climb Bio, Inc.: Climb Bio Appoints Perrin Wilson, Ph.D., as Chief Business Officer354WELLESLEY HILLS, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM) announced today the appointment of Perrin Wilson, Ph.D. as Chief Business Officer. Dr. Wilson is an accomplished...
► Artikel lesen
10.01.Climb Bio enters licensing deal with Mabworks for CLYM116 development1
10.01.Climb Bio, Inc. - 8-K, Current Report-
09.01.Climb Bio, Inc.: Climb Bio Expands Pipeline Through an Exclusive License to Develop and Commercialize an Antibody Targeting the APRIL Pathway for IgA Nephropathy225Transaction Expands Climb Bio's Pipeline of B-cell Targeted Therapeutics to Address Immune-mediated Diseases New Program is a Highly Potent, Fc-engineered anti-APRIL Monoclonal Antibody Specifically...
► Artikel lesen
19.12.24Climb Bio, Inc.: Climb Bio to be Added to the Nasdaq Biotechnology Index133WELLESLEY HILLS, Mass., Dec. 19, 2024 (GLOBE NEWSWIRE) -- December 19, 2024 - Climb Bio, Inc. (Nasdaq: CLYM) today announced that the company will be added to the NASDAQ Biotech Index (Nasdaq: NBI)...
► Artikel lesen
24.10.24Woodforest Acceptance Solutions Partners With Clym to Enhance Website Accessibility and Compliance With Consumer Privacy Regulations312Woodforest Acceptance Solutions Partners with Clym to Enhance Merchants' Compliance and Website Accessibility, Empowering Businesses to Navigate Digital Regulations Seamlessly THE WOODLANDS, TX / ACCESSWIRE...
► Artikel lesen
02.10.24Eliem Therapeutics, Inc.: Eliem Therapeutics Announces Rebranding and Corporate Name Change to Climb Bio, Inc.186Name change to "Climb Bio" marks the Company's transition and focus on developing treatments for immune-mediated diseases Climb Bio will begin trading on Nasdaq under the trading symbol "CLYM" effective...
► Artikel lesen
25.09.24Pre-market Movers: Stitch Fix, Motorsport Games, Eliem Therapeutics, Banzai International, VS MEDIA837BEIJING (dpa-AFX) - The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 07.35 A.M. ET).In the Green Motorsport Games Inc. (MSGM) is up over 25% at...
► Artikel lesen
14.08.24Eliem Therapeutics, Inc.: Eliem Therapeutics Reports Second Quarter Financial Results119Eliem completed the acquisition of Tenet Medicines and concurrent $120 million private placement Eliem to host an Investor Day later in the year to provide an overview of budoprutug (previously referred...
► Artikel lesen
28.06.24Eliem Therapeutics, Inc.: Eliem Therapeutics Announces its Addition to the Russell 2000 and Russell 3000 Indexes242SEATTLE and CAMBRIDGE, United Kingdom, June 28, 2024 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (Nasdaq: ELYM), announced today that the Company will be included in the Russell 2000® Index and the...
► Artikel lesen
Seite:  Weiter >>
21 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1